Reinterpreting Conflicting BRCA1 Variants for Better Diagnosis
Author Information
Author(s): So Min-Kyung, Koh Hyun-Jeong, Park Sholhui, Jeong Tae-Dong, Huh Jungwon
Primary Institution: Ewha Womans University College of Medicine
Hypothesis
Can the use of VarSome and CanVIG-UK improve the interpretation of conflicting BRCA1 missense variants?
Conclusion
The study found that VarSome and CanVIG-UK have different strengths in classifying BRCA1 variants, which can enhance clinical decision making.
Supporting Evidence
- The overall concordance rate between VarSome and CanVIG-UK was 58.9%.
- VarSome classified 64.0% of variants as benign, while CanVIG-UK classified 51.6% as variants of uncertain significance.
- 17 out of 450 variants reached a consensus classification in ClinVar by May 2024.
Takeaway
This study looked at 450 confusing genetic variants related to breast cancer and found that two tools can help doctors understand them better.
Methodology
The study compared classifications of BRCA1 missense variants using VarSome and CanVIG-UK, analyzing their concordance and consensus classifications.
Potential Biases
The reliance on automated tools without manual intervention may introduce biases in variant classification.
Limitations
The study only focused on BRCA1 missense variants and did not include other variant types, and the automated classification by VarSome may miss some details.
Statistical Information
Confidence Interval
95% CI: 52.0–66.4%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website